Lawson Lundell Advises Roivant Sciences Ltd. in the formation of Genevant Sciences with $37.5M in Transaction-Related Seed Capital and Platform to Develop RNA Therapeutics
On April 12, 2018, Arbutus Biopharma Corporation (“Arbutus”), an industry-leading hepatitis B virus (HBV) therapeutic solutions company and Roivant Sciences Ltd. (“Roivant”) announced that they have entered into an agreement to launch Genevant Sciences (“Genevant”), a jointly-owned company focused on the discovery, development, and commercialization of a broad range of RNA-based therapeutics. Under the terms of the agreement, Roivant will contribute $37.5 million in transaction-related seed capital for Genevant.
Lawson Lundell LLP acted as lead Canadian counsel for Roivant with a team led by Valerie Mann, and including Crispin Arthur (Corporate), Leonard Glass (Tax), Deborah Cushing (Labour & Employment) and Andrew Mildenhall (Leasing). Lawson Lundell assisted Allen Waxman, Averill Powers, David Jakus, Selina Anabwani, Kenneth Peist of Roivant's internal legal group.